At least 2000 patients to receive new Covid-19 therapy in clinical trial

An antibody treatment that could lessen the impact of Covid-19 is to be trialled on patients in UK hospitals. The Recovery trial, co-ordinated by the University of Oxford, will assess the impact of giving patients REGN-COV2 alongside usual standard care to see if it lessens the severity of Covid-19 and can reduce deaths. In June, the Recovery trial, which includes 176 UK hospital sites, found that a cheap steroid called dexamethasone could save the lives of people with severe Covid infection. In the new phase 3 study, at least 2,000 patients will be randomly allocated to receive REGN-COV2 plus usual care, and the results will be compared with at least 2,000 patients not on the therapy.